Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib
Authors
Keywords
Cross-resistance, Lysosomes, Tyrosine kinase inhibitor, mTOR inhibitor
Journal
CELLULAR ONCOLOGY
Volume 38, Issue 2, Pages 119-129
Publisher
Springer Nature
Online
2015-02-10
DOI
10.1007/s13402-015-0218-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer
- (2014) Ramona Rudalska et al. NATURE MEDICINE
- Downregulation of signal transducer and activator of transcription 3 by sorafenib: A novel mechanism for hepatocellular carcinoma therapy
- (2014) Man-Hsin Hung WORLD JOURNAL OF GASTROENTEROLOGY
- Relationship between therapeutic efficacy of doxorubicin-transferrin conjugate and expression of P-glycoprotein in chronic erythromyeloblastoid leukemia cells sensitive and resistant to doxorubicin
- (2014) Marzena Szwed et al. CELLULAR ONCOLOGY
- Pazopanib after sunitinib failure in patients with metastatic renal cell carcinoma
- (2013) Juhana Rautiola et al. ACTA ONCOLOGICA
- Metastatic renal cell carcinoma: how to make the best sequencing decision after withdrawal for intolerance to a tyrosine kinase inhibitor
- (2013) Roberto Sabbatini et al. Future Oncology
- Emerging Paradigms in the Development of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer
- (2013) Justin F. Gainor et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Trial of Temsirolimus Versus Sorafenib As Second-Line Therapy After Sunitinib in Patients With Metastatic Renal Cell Carcinoma
- (2013) Thomas E. Hutson et al. JOURNAL OF CLINICAL ONCOLOGY
- Sunitinib and SU11652 Inhibit Acid Sphingomyelinase, Destabilize Lysosomes, and Inhibit Multidrug Resistance
- (2013) A.-M. Ellegaard et al. MOLECULAR CANCER THERAPEUTICS
- Drug rechallenge and treatment beyond progression—implications for drug resistance
- (2013) Elizabeth A. Kuczynski et al. Nature Reviews Clinical Oncology
- Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
- (2013) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer
- (2013) Nir Peled et al. CELLULAR ONCOLOGY
- Successful Treatment of Renal Cell Carcinoma With Sorafenib After Effective but Hepatotoxic Sunitinib Exposure
- (2012) Hans M. Westgeest et al. JOURNAL OF CLINICAL ONCOLOGY
- Modulation of Akt/mTOR Signaling Overcomes Sunitinib Resistance in Renal and Prostate Cancer Cells
- (2012) P. B. Makhov et al. MOLECULAR CANCER THERAPEUTICS
- HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors
- (2012) S Gusenbauer et al. ONCOGENE
- EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib
- (2012) Ryan B. Corcoran et al. Cancer Discovery
- Autocrine CSF-1 and CSF-1 Receptor Coexpression Promotes Renal Cell Carcinoma Growth
- (2011) J. Menke et al. CANCER RESEARCH
- Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer
- (2011) H. Yang et al. CANCER RESEARCH
- Lysosomal Sequestration of Sunitinib: A Novel Mechanism of Drug Resistance
- (2011) K. J. Gotink et al. CLINICAL CANCER RESEARCH
- PRKX, TTBK2 and RSK4 expression causes sunitinib resistance in kidney carcinoma- and melanoma-cell lines
- (2011) Claus Bender et al. INTERNATIONAL JOURNAL OF CANCER
- Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity
- (2011) Theonie Anastassiadis et al. NATURE BIOTECHNOLOGY
- Lysosomal membrane proteins: life between acid and neutral conditions: Figure 1
- (2010) Paul Saftig et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- Interleukin-8 Mediates Resistance to Antiangiogenic Agent Sunitinib in Renal Cell Carcinoma
- (2010) D. Huang et al. CANCER RESEARCH
- Synergistic Antitumor Activity of Sorafenib in Combination with Epidermal Growth Factor Receptor Inhibitors in Colorectal and Lung Cancer Cells
- (2010) E. Martinelli et al. CLINICAL CANCER RESEARCH
- A Multicenter Phase II Study of Erlotinib and Sorafenib in Chemotherapy-Naive Patients with Advanced Non-Small Cell Lung Cancer
- (2010) J. S. W. Lind et al. CLINICAL CANCER RESEARCH
- Simple and selective method for the determination of various tyrosine kinase inhibitors used in the clinical setting by liquid chromatography tandem mass spectrometry
- (2010) R. Honeywell et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- Reversible Epithelial to Mesenchymal Transition and Acquired Resistance to Sunitinib in Patients with Renal Cell Carcinoma: Evidence from a Xenograft Study
- (2010) H. J. Hammers et al. MOLECULAR CANCER THERAPEUTICS
- Sorafenib Induces Growth Arrest and Apoptosis of Human Glioblastoma Cells through the Dephosphorylation of Signal Transducers and Activators of Transcription 3
- (2010) Fan Yang et al. MOLECULAR CANCER THERAPEUTICS
- Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors
- (2009) R Kumar et al. BRITISH JOURNAL OF CANCER
- Sunitinib Inhibition of Stat3 Induces Renal Cell Carcinoma Tumor Cell Apoptosis and Reduces Immunosuppressive Cells
- (2009) H. Xin et al. CANCER RESEARCH
- Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib
- (2009) Henk J. Broxterman et al. DRUG RESISTANCE UPDATES
- Synergistic proapoptotic effects of the two tyrosine kinase inhibitors pazopanib and lapatinib on multiple carcinoma cell lines
- (2009) K A Olaussen et al. ONCOGENE
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
- Mechanisms of Myocyte Cytotoxicity Induced by the Multiple Receptor Tyrosine Kinase Inhibitor Sunitinib
- (2008) B. B. Hasinoff et al. MOLECULAR PHARMACOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now